title: Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
abstract: OBJECTIVE
  After successful endoscopic hemostasis in bleeding peptic ulcer, addition of proton pump inhibitors reduce the rate of recurrent bleeding by maintaining intragastric pH at neutral level. The aim of the present study was to evaluate the effect of various proton pump inhibitors given through different routes on intragastric pH over 72 h after endoscopic hemostasis in bleeding peptic ulcer.
  
  
  METHODS
  Ninety consecutive patients who had successful endoscopic therapy of bleeding peptic ulcer underwent 72-h continuous ambulatory intragastric pH study, were randomly assigned to receive p.o. omeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h or i.v. 80 mg omeprazole followed by infusion 8 mg/h for 72 h. Oral pantoprazole 80 mg bolus followed by 80 mg every 12 h for 72 h or i.v. 80 mg pantoprazole followed by infusion of 8 mg/h for 72 h. Oral rabeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h or i.v. 80 mg rabeprazole followed by infusion 8 mg/h for 72 h. Five patients received no treatment after successful endoscopic therapy and underwent 72-h pH study.
  
  
  RESULTS
  Mean 72-h intragastric pH for p.o. omeprazole was 6.56 versus 6.93 for omeprazole infusion (P = 0.48). Mean 72-h intragastric pH for p.o. pantoprazole was 6.34 versus 6.32 for pantoprazole infusion (P = 0.62). Mean 72-h intragastric pH for rabeprazole p.o. was 6.11 versus 6.18 rabeprazole i.v. (P = 0.55). Mean 72-h pH for the no proton pump inhibitor group was 2.04.
  
  
  CONCLUSIONS
  There was no significant difference among various proton pump inhibitors given through different routes on raising intragastric pH above 6 for 72 h after successful endoscopic hemostasis in bleeding peptic ulcer.
authors.affiliation: Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India. gul_javid@rediffmail.com
authors.forename: Gul
authors.initials: G
authors.lastname: Javid
authors.forename: Showkat Ali
authors.initials: SA
authors.lastname: Zargar
authors.forename: Riyaz-
authors.initials: R
authors.lastname: U-Saif
authors.forename: Bashir Ahmad
authors.initials: BA
authors.lastname: Khan
authors.forename: Ghulam Nabi
authors.initials: GN
authors.lastname: Yatoo
authors.forename: Altaf Hussain
authors.initials: AH
authors.lastname: Shah
authors.forename: Ghulam Mohammad
authors.initials: GM
authors.lastname: Gulzar
authors.forename: Jaswinder Singh
authors.initials: JS
authors.lastname: Sodhi
authors.forename: Mushtaq Ahmad
authors.initials: MA
authors.lastname: Khan
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000628:therapy*; D004384:Duodenoscopy; D005260:Female; D005745:Gastric Acidity Determination; D005773:Gastroscopy; D006489:Hemostatic Techniques; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D000077402:Pantoprazole; D010438:Peptic Ulcer Hemorrhage / Q000517:prevention & control / Q000628:therapy*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D064750:Rabeprazole; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D000077402:Pantoprazole; D009853:Omeprazole